Sertraline hydrochloride：Introduction and Side effects

Introduction of Sertraline hydrochloride

Sertraline hydrochloride is an antidepressant that belongs to a group of medications called selective serotonin reuptake inhibitors (SSRIs). Liver first-pass effects occur after oral administration, so studies have been done to improve its therapeutic effect by transdermal administration. It is used to treat major depression, obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder (SAD), post-traumatic stress disorder (PTSD) and severe premenstrual syndrome (premenstrual anxiety disorder). A small number of children, adolescents and young adults (under 24 years of age) have developed suicidal tendencies (contemplating harm or suicide or planning or attempting to do so) after taking an antidepressant such as Sertraline hydrochloride during clinical studies.

Side effects of Sertraline hydrochloride

Side effects that may occur in the treatment of depression include: nausea, dizziness, drowsiness, dry mouth, loss of appetite, increased sweating, diarrhoea, upset stomach or difficulty sleeping. Severe may result in: unusual weight loss; fast or irregular heartbeat; fainting, black stools, vomit that looks like coffee grounds; eye pain, swelling, and redness; pupil enlargement, vision changes (e.g., seeing rainbows around lights at night, blurred vision).

In the clinical study of paroxetine sertraline hydrochloride for the treatment of post-stroke depression, 58 cases of post-stroke depression patients were selected as research subjects, 29 cases in the control group were given paroxetine treatment, and 29 cases in the experimental group were given sertraline hydrochloride treatment. The clinical efficacy and safety of the two groups were compared and summarised. The results showed that before treatment, the differences between the anxiety self-assessment scale (SAS) scores and depression self-assessment scale (SDS) scores of the two groups were not statistically significant (p < 0.05). At 2w, 5w, and 7w after treatment, negative mood improved significantly, and the difference in scores between the two groups at the two times after treatment was not statistically significant (p < 0.05). However, comparing the two groups in terms of adverse reactions, the total incidence of adverse reactions in the experimental group was significantly lower than that in the control group, and the difference was statistically significant (p < 0.05). It can be seen that both sertraline hydrochloride and paroxetine hydrochloride can achieve ideal results in the treatment of post-stroke depression, which helps to improve the negative emotions of patients. However, in contrast, sertraline hydrochloride has fewer adverse reactions, indicating that it is safer and worth promoting its use in the clinic.

References:

[1] FU B, MENG S. Clinical Effect and Safety Evaluation of Paroxetine and Sertraline Hydrochloride Used for Depression Treatment after Cerebral Stroke[C]. 2018: 0. DOI:10.25236/icmbmm.2018.76.

You may like